Tom Knight, CEO of Invistics Corp.
The National Institutes of Health (NIH) has made additional funds available to Invistics Corp., based in Atlanta, to make its software even more effective at detecting drug diversion in anesthesiology.
The company received its first NIH grant, a little more than $1 million, in 2017. The supplemental amount received last December and this July is a matching grant, for a total of over $2 million to date.
Dozens of U.S. hospitals currently use Invistics’